April 2024 - PsychedelicNewsWire (PNW)

TuesdayApr 30, 2024 10:00 am

DEA Tells Court That Right to Try Law Doesn’t Supersede CSA in Psilocybin Case

The U.S. Drug Enforcement Administration (DEA) is claiming that a federal law that affords severely ill individuals the right to try investigational medications doesn’t apply to drugs classified under the Controlled Substances Act. This is in response to a lawsuit filed by a doctor in Washington state who sought permission to legally administer psilocybin as treatment for patients in end-of-life care with cancer. The agency argues that because drugs classified under Schedule I are said to have no accepted medical use, the law prevents them from being dispensed, even by professionals. The doctor in question, Dr. Sunil Aggarwal, has been…

ThursdayApr 25, 2024 10:00 am

Study Shows Ayahuasca’s Painkiller Effects in Mice, No Toxic Effects

Ayahuasca is a psychoactive brew that has been used for centuries by Indigenous cultures in South America for divination, spiritual ceremonies and healing. It is made from the Psychotria viridis shrub and the Banisteriopsis caapi vine, which contain DMT and harmala alkaloids, respectively. Interest in ayahuasca has grown in Europe and the United States over the last couple of years as people learn more about the brew’s potential therapeutic benefits in treating mental-health conditions such as anxiety, post-traumatic stress disorder and depression. Now, new research has found that the brew can be used as a painkiller without any toxic effects.…

TuesdayApr 23, 2024 10:00 am

Study Says Psychedelics Can Boost Sexual Satisfaction, Functioning

New research has looked into the influence of psychedelic substances on sexual functioning and satisfaction. This comes as scientists learn more about the promising potential of psychedelics in treating mental-health conditions. Various studies have looked into the effectiveness of psilocybin in alleviating symptoms of anxiety. Psilocybin, the primary psychedelic compound found in different species of hallucinogenic mushrooms, has also shown comparable effectiveness to escitalopram in reducing symptoms of depression in patients with major depressive disorder. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. SSRIs have different side effects, a common one being sexual dysfunction. Sexual dysfunction may lower an…

ThursdayApr 18, 2024 10:00 am

Therapist Explains What Psychedelics Do, What Talk Therapy Can’t

Interest in the use of psychedelics in therapy has increased over the last couple of years, with researchers finding that drugs such as psilocybin, LSD and ketamine may be useful in the treatment of different mental-health conditions. According to one therapist, psychedelics are drugs that enable the dissolution of the individual ego. This is the objective of many spiritual traditions, where one realizes that they aren’t an individual island living a separate life but a smaller cog in a huge machine. By the aforementioned definition, psychedelics include ayahuasca, DMT, ketamine, psilocybin and LSD. It is important to note MDMA is…

TuesdayApr 16, 2024 10:00 am

AMA Study Finds Treating Mental-Health Issues with Psilocybin Doesn’t Increase Paranoia Risk

A recently published review has determined that using psilocybin to manage mental-health conditions doesn’t heighten the risk of paranoia. This discovery comes at a time when public interest in the therapeutic potential of psychedelics is increasing. The review was carried out by researchers at Larkin University, the University of Georgia and Palm Beach Atlantic University, who were focused on better understanding the potential negative effects of psilocybin therapy. For their study, the researchers reviewed six randomized, double-blind clinical trials with a total of 528 patients, where psilocybin was administered to treat depression and anxiety. They used ClinicalTrials.gov, Web of Science…

ThursdayApr 11, 2024 10:00 am

Psilocybin Could Help in Combating Diabetes

Diabetes is a chronic illness characterized by high levels of blood sugar. There are different types of diabetes, the most common being types I and II. Latest data estimates that by 2045, more than 700 million individuals globally could be afflicted with the illness as its prevalence continued to rise. Researchers have commenced studies into whether psilocybin may help fight the effects of diabetes. Psilocybin is the primary psychoactive compound found in various species of hallucinogenic mushrooms. In the last couple of years, the compound’s therapeutic potential has been recognized, particularly for mental health disorders such as anxiety, depression and…

TuesdayApr 09, 2024 10:00 am

Missouri to Use $10M from Opioid Funds to Study Psilocybin

Legislators in the House of Representatives in the state of Missouri have awarded preliminary approval to a budget measure that would allocate $10 million from opioid settlement funds to study grants focused on researching psilocybin’s use in treating opioid-use disorder. The initiative, HB 2010, was amended in the House. One amendment made in a committee last week would have allocated the $10 million toward conducting research on ibogaine as an opioid-use disorder treatment. This provision was modified to fund studies on psilocybin instead. Ibogaine’s addition to HB 2010 was facilitated by Representative Chad Perkins, a long-time law enforcement officer. The…

ThursdayApr 04, 2024 10:00 am

More Psychedelic Users Reporting Symptoms of HPPD

Hallucinogenic persistent perception disorder (HPPD) is an intoxication disorder caused by psychedelic drugs that encompasses a range of visual disturbances that occur in different time frames. The disorder also causes extreme anxiety as well as out-of-body sensations and is marked by shame as well as stigma. There are two types of HPPD; the first is characterized by brief flashbacks, while individuals with the second type of HPPD experience symptoms that can last anywhere between a couple of months to their whole lives. Dr. Anneliese McConnell, a researcher at Western Sydney University, reports that HPPD affects more than 5% of psychedelic…

TuesdayApr 02, 2024 10:00 am

Research Findings Promising as Scientists Study Placebo Effect in Psychedelic Treatment

Recent research assessed how patient expectations influenced the outcomes of psychedelic treatments in comparison to conventional treatments. This comes as the global impact of depression is being felt in different parts of the world and the need for alternative treatments increases. For a long time, selective serotonin re-uptake inhibitors (SSRIs) have been prescribed to manage depression. While these drugs do perform better than placebos, they aren’t effective for all individuals. Psychedelic-assisted therapy has been heralded as a new approach to manage mental-health conditions such as depression, promising a range of benefits with only a few sessions. However, some questions on…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Month: April 2024